Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06378944 | Selective Sentinella Lymph Node Biopsy with Indocyanine Green in Patients with Breast Cancer(INSEAN) | recruiting | — | 15,000 | Omphis FoundationOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06559696 | Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy | recruiting | Phase 3 | 722 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 |
| clinicaltrials |
| NCT06591039 | A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China | recruiting | — | 20,000 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06595966 | Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery | recruiting | — | 80 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06331169 | Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer | recruiting | Phase 1 | 42 | Fudan UniversityOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT03827317 | HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer | recruiting | N/A | 24 | Imperial College LondonOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06566937 | The Effectiveness of E-health Intervention in Improving Mental Health Outcomes Among Breast Cancer Patients | recruiting | N/A | 114 | National University of MalaysiaOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06197581 | Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer(RADIOCOM) | recruiting | N/A | 148 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06176534 | Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial | recruiting | Phase 2 | 240 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06548919 | Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer | recruiting | — | 450 | SciClone PharmaceuticalsINDUSTRY | 1 | Aug 12, 2024 | clinicaltrials |
| NCT04679454 | Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer | recruiting | N/A | 79 | European Institute of OncologyOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06503380 | Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer | recruiting | — | 1,000 | Fudan UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03577197 | Southeast Netherlands Advanced Metastatic Breast Cancer Registry(SONABRE) | recruiting | — | 7,000 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06508216 | A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer(COMPASS-TNBC) | recruiting | Phase 1 / Phase 2 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06236269 | HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan(ACROSS-TROP2) | recruiting | Phase 2 | 50 | SOLTI Breast Cancer Research GroupOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT04353557 | ctDNA Monitoring in Early Breast Cancer | recruiting | — | 200 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05549024 | 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients | recruiting | Early Phase 1 | 90 | Peking Union Medical College HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05635487 | A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | recruiting | Phase 2 | 65 | Shengjing HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04531696 | UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research(UPTIDER) | recruiting | N/A | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04790305 | Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | recruiting | Phase 4 | 1,072 | Fudan UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | recruiting | Phase 1 | 40 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06472583 | Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer(BREAST-BOOSTER) | recruiting | Phase 2 | 78 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05216900 | Breast Reconstruction and Neoadjuvant Radiotherapy(BRENAR) | recruiting | N/A | 20 | UMC UtrechtOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05720260 | Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | recruiting | Phase 2 | 42 | National Taiwan University HospitalOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06345534 | FAST-FORWARD vs HAI5 | recruiting | N/A | 740 | University Hospital, GhentOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT05460975 | Breast Cancer Risk From Sonographic Glandular Tissue Component (or International GTC Study) | recruiting | — | 16,164 | Seoul National University HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03815890 | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO(BELLINI) | recruiting | Phase 2 | 80 | The Netherlands Cancer InstituteOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05851053 | Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study(BLOC-II) | recruiting | — | 455 | University Medical Center GroningenOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06389006 | To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer | recruiting | Phase 2 | 79 | RemeGen Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT06426810 | Electrosurgical Bipolar Systems Versus Conventional Electrocautery After SLNBx | recruiting | N/A | 40 | SMG-SNU Boramae Medical CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT06425874 | The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery | recruiting | — | 1,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06313086 | DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 442 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 10, 2024 | clinicaltrials |
| NCT06214598 | Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors(AID) | recruiting | N/A | 90 | University of BelgradeOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06404697 | Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients | recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06401304 | Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value)(OncoPROValue-1) | recruiting | — | 1,200 | Uppsala UniversityOTHER | 3 | May 6, 2024 | clinicaltrials |
| NCT06385990 | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | recruiting | Phase 2 | 53 | Hunan Cancer HospitalOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT02897700 | A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast(COC-IDCB) | recruiting | Phase 1 | 300 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04603209 | Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer | recruiting | — | 1,000 | Saint John's Cancer InstituteOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06149130 | Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer | recruiting | Phase 2 | 82 | Tongji HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05800132 | Diagnostic Performance of Breast Cancer Screening Second Reading Process Assisted by AI(IMA-L2) | recruiting | N/A | 5,000 | TherapixelINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06341621 | Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib(Rainbow) | recruiting | Phase 3 | 1,900 | Fudan UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06334471 | Whole Genome Sequencing in Breast Cancer(WGS SIT) | recruiting | — | 1,200 | Inocras Korea Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06341894 | Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer | recruiting | Phase 2 | 1,163 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06340516 | NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity | recruiting | N/A | 700 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06330012 | The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients. | recruiting | N/A | 50 | Samsung Medical CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06330870 | Brain Metastasis Development Mechanism in BCBM Patients | recruiting | N/A | 30 | Samsung Medical CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT05433753 | Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study | recruiting | — | 60 | National Cancer Center, JapanOTHER_GOV | 1 | Mar 25, 2024 | clinicaltrials |
| NCT05861271 | Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer | recruiting | Phase 2 | 1,008 | Fudan UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials